Azacitidine.

Article Details

Citation
Copy to clipboard

Issa JP, Kantarjian H

Azacitidine.

Nat Rev Drug Discov. 2005 May;Suppl:S6-7.

PubMed ID
15962522 [ View in PubMed
]
Abstract

Azacitidine (Vidaza; Pharmion), an inhibitor of DNA methylation, was approved by the US FDA for the treatment of myelodysplastic syndromes in May 2004. It is the first drug to be approved by the FDA for treating this rare family of bone-marrow disorders, and has been given orphan-drug status. It is also a pioneering example of an agent that targets 'epigenetic' gene silencing, a mechanism that is exploited by cancer cells to inhibit the expression of genes that counteract the malignant phenotype.

DrugBank Data that Cites this Article

Drugs